Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladarixin in New-onset Type 1 Diabetes with Preserved Beta-cell Function
NCT04899271Phase 2Terminated
- Sponsor
- Dompé
- Start
- Dec 2020
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of ladarixin in type 1 diabetes mellitus (T1D), sponsored by Dompé. Started Dec 2020; status: terminated.
02
Drugs
ladarixin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04899271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899271.